Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Study ID
NCT01260506
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Glioblastoma Multiforme

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VB-111 — DRUG
  • Bevacizumab — DRUG
    Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab

Study Details

The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.

Key Dates

First listed
Dec 15, 2010
Start date
Dec 31, 2010
Status verified
Apr 2020
Primary completion
Jul 23, 2015
Completion
Dec 20, 2018

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: VB-111
    Antiangiogenic and vascular disruptive agent

Primary Outcome Measure

Overall Survival [ Time Frame: From date of study entry until the date of death from any cause (up to 10 years) ]

Locations (3)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts--
Duke University Medical CenterDurhamNorth Carolina--
Uthsc- CtrcSan AntonioTexas--

Find similar trials in Boston, MA

By research site
Dana Farber Cancer Institute· Boston, MADuke University Medical Center· Durham, NCUthsc- Ctrc· San Antonio, TX

Related Studies